Journal of vascular and interventional radiology : JVIR · 2026
Impact of Genetic Mutations on Response and Time to Progression after Radioembolization of Breast Cancer Liver Metastases.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bajnauth Daana, Deipolyi Amy, Annie Frank, Bryce Yolanda
Аннотация
PURPOSE: To evaluate the association between genetic mutations and clinical outcomes, including response and time to progression, in patients with breast cancer liver metastases treated with yttrium-90 (90Y) radioembolization.
MATERIALS AND METHODS: A retrospective, single-institution study of 110 female patients with breast cancer liver metastases who underwent 90Y radioembolization and genomic profiling using MSK-IMPACT was performed. Patient demographics and treatment response were collected from electronic medical records and picture archiving and communication system (PACS). 90Y response was categorized as complete, partial, none, or progression. Time to progression was analyzed in patients with an initial response. Median survival using Kaplan-Meier estimation was correlated to genetic mutations. Seventeen patients died before progression was assessed, and 6 patients were not yet evaluated postprocedurally.
RESULTS: Overall median survival was 32.8 months (interquartile range [IQR], 1.3-173.0 months). Patients with the ERBB2 mutation showed the longest median survival (70.2 months [IQR, 12.5-173.0 months]), whereas the RAD21 mutation had the shortest median survival (25.5 months [IQR, 2.4-173.0 months]). KDM5C and CBFB mutations were associated with the highest response rates (100%, P = .003 and P = .014, respectively), whereas the H3C13 mutation was associated with the lowest response rate (0%, P = .002). Median time to progression was 32.8 months (IQR, 1.4-173.0 months) in patients with an initial treatment response. The H3F3B mutation was associated with the longest time to progression (105 months [IQR, 50.2-105.0 months]), whereas the RUNX1 mutation was associated with the shortest time to progression (1.4 months [IQR,1.4-36.5 months]).
CONCLUSIONS: Specific genetic mutations are associated with survival, response rate, and time to progression after 90Y radioembolization. This study underscores the potential use of genetic profiling to individualize treatment plans.
MATERIALS AND METHODS: A retrospective, single-institution study of 110 female patients with breast cancer liver metastases who underwent 90Y radioembolization and genomic profiling using MSK-IMPACT was performed. Patient demographics and treatment response were collected from electronic medical records and picture archiving and communication system (PACS). 90Y response was categorized as complete, partial, none, or progression. Time to progression was analyzed in patients with an initial response. Median survival using Kaplan-Meier estimation was correlated to genetic mutations. Seventeen patients died before progression was assessed, and 6 patients were not yet evaluated postprocedurally.
RESULTS: Overall median survival was 32.8 months (interquartile range [IQR], 1.3-173.0 months). Patients with the ERBB2 mutation showed the longest median survival (70.2 months [IQR, 12.5-173.0 months]), whereas the RAD21 mutation had the shortest median survival (25.5 months [IQR, 2.4-173.0 months]). KDM5C and CBFB mutations were associated with the highest response rates (100%, P = .003 and P = .014, respectively), whereas the H3C13 mutation was associated with the lowest response rate (0%, P = .002). Median time to progression was 32.8 months (IQR, 1.4-173.0 months) in patients with an initial treatment response. The H3F3B mutation was associated with the longest time to progression (105 months [IQR, 50.2-105.0 months]), whereas the RUNX1 mutation was associated with the shortest time to progression (1.4 months [IQR,1.4-36.5 months]).
CONCLUSIONS: Specific genetic mutations are associated with survival, response rate, and time to progression after 90Y radioembolization. This study underscores the potential use of genetic profiling to individualize treatment plans.
Предметные рубрики MeSH
HumansFemaleRadioembolization, TherapeuticLiver NeoplasmsRetrospective StudiesMutationBreast NeoplasmsTime FactorsMiddle AgedAgedDisease ProgressionYttrium RadioisotopesRadiopharmaceuticalsTreatment OutcomeRisk FactorsBiomarkers, TumorPhenotypeGenetic Predisposition to DiseaseAdultErb-b2 Receptor Tyrosine Kinases